CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
尽管未能诱导或维持 B 细胞发育不全，CD19 靶向 CAR-T 再输注仍实现持久缓解，以及 tisagenlecleucel 再输注的单中心经验
英文原题：Durable remissions achieved with reinfusion of CD19-directed CAR-T despite failure to induce or maintain B-cell aplasia and single-center experience with reinfusion of tisagenlecleucel.
查看英文原题
Durable remissions achieved with reinfusion of CD19-directed CAR-T despite failure to induce or maintain B-cell aplasia and single-center experience with reinfusion of tisagenlecleucel.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CD19靶向CAR-T 淋巴细胞（CAR-T）已使难治性和/或多次复发B淋巴细胞白血病患儿获得持久缓解。对于CAR-T 治疗后复发或B细胞缺失消失的患者，再次输注CAR-T 的作用尚不明确。我们报告两例接受tisagenlecleucel再次输注后获得持久缓解的病例，尽管患者未能达到或维持B细胞缺失；同时，将这两例与本中心另外6名接受多次tisagenlecleucel输注的患儿进行比较。我们的经验提示，再次输注是安全的，可能成为少数患者的根治性治疗。再次输注也可重新诱导缓解和/或B细胞缺失，从而为后续治疗创造条件。
展开英文摘要原文
CD19-directed chimeric antigen receptor T lymphocytes (CAR-T) have led to durable remissions in children with refractory and/or multiply relapsed B-lymphoblastic leukemia. For those who relapse or lose B-cell aplasia post CAR-T, the role of CAR-T reinfusion is unclear.
We report two cases of durable remission with tisagenlecleucel reinfusion despite failure to achieve or maintain B-cell aplasia, and compare these cases to six additional children who received multiple tisagenlecleucel infusions at our institution.
Our experience suggests that reinfusion is safe and may be a definitive therapy for a small subset of patients. Reinfusion can also reintroduce remission and/or B-cell aplasia, allowing for subsequent therapies.
论文信息
- 作者
- Galletta TJ、Rubinstein JD、Krupski C、Nelson AS、Khoury R、Dandoy CE、Davies SM、Phillips CL
- 第一作者单位
- Cincinnati Children's Hospital Medical Center Cancer and Blood Diseases Institute, Cincinnati, Ohio, USA.United States
- 通讯作者单位
- Cincinnati Children's Hospital Medical Center Division of Oncology, Cincinnati, Ohio, USA.United States
- 期刊
- Pediatric blood & cancer2023 May
- 原文标识
- PubMed 36815392 · DOI 10.1002/pbc.30271